Xcovery, Inc.

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included

The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including risi

Innovation is undoubtedly the key element in China’s healthcare investment scenario and early-stage venture capital funds continue to back home-grown new drug development with a total of 15 deals in t